Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04560738
Other study ID # CC-92480-CP-004
Secondary ID U1111-1257-8762
Status Completed
Phase Phase 1
First received
Last updated
Start date October 15, 2020
Est. completion date May 13, 2021

Study information

Verified date November 2021
Source Celgene
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single-center, open-label study to be conducted in healthy adult male participants. This study is designed to characterize the biotransformation and excretion of [14C]-CC-92480 and to evaluate the safety and tolerability of [14C]-CC-92480 following a single oral dose of [14C]-CC-92480.


Recruitment information / eligibility

Status Completed
Enrollment 8
Est. completion date May 13, 2021
Est. primary completion date May 13, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: Participants must satisfy the following criteria to be enrolled in the study: 1. Participant is = 18 and = 55 years of age at the time of signing the informed consent form (ICF). 2. Participant is male. 3. Participant must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted. 4. Participant is willing and able to adhere to the study visit schedule and other protocol requirements. 5. Participant is in good health, as determined by the Investigator at the time of signing the ICF. 6. Participant agrees to abide by the requirements and restrictions outlined in the CC-92480 Pregnancy Prevention Plan for Participants in Clinical Trials. 7. Participant must practice true abstinence or agree to use a barrier method of birth control (condoms not made out of natural [animal] membrane [latex condoms are recommended]) during sexual contact with a pregnant female or a FCBP while participating in the study and for at least 90 days following administration of CC-92480, even if he has undergone a successful vasectomy. A FCBP is a female who: 1) has achieved menarche at some point; 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months). 8. Participant has a body mass index (BMI) = 18 and = 33 kg/m2 at the time of signing the ICF. 9. Participant has clinical laboratory safety test results, including alanine aminotransferase (ALT)/aspartate aminotransferase (AST) results, that are within normal limits or considered not clinically significant by the Investigator. 1. Platelet count and absolute lymphocyte count (ALC) must be above the lower limit of normal at screening. 2. Absolute neutrophil counts (ANC) must be greater than 2500/microliter. 10. Participant is afebrile, with supine systolic BP = 90 and = 140 mm Hg, supine diastolic BP = 50 and = 90 mm Hg, and pulse rate = 40 and = 110 bpm at screening. 11. Participant has a normal or clinically acceptable 12-lead ECG, with a QT interval corrected for heart rate using Fridericia's formula (QTcF) value = 430 msec, at screening. Exclusion Criteria: The presence of any of the following will exclude a participant from enrollment: 1. Participant has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from participating in the study. 2. Participant has a history of chronic pruritus or clinically significant chronic dermatologic disorder. 3. Participant has contraindication or intolerance to first-generation antihistamine medications. 4. Participant has a history of benign ethnic neutropenia. 5. Participant has a history of any clinically significant and relevant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, allergic disease, drug allergies, or other major disorders as determined by the Investigator. 6. Participant has any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he were to participate in the study. 7. Participant has any condition that confounds the ability to interpret data from the study. 8. Participant was exposed to an investigational drug (new chemical entity) within 30 days prior to dosing or 5 half-lives of that investigational drug, if known (whichever is longer). 9. Participant has used any prescribed systemic or topical medication (including but not limited to analgesics, anesthetics, etc) within 14 days or 5 half-lives of that medication, whichever is longer, prior to dosing. 10. Participant has used any non-prescribed systemic or topical medication (including vitamin/mineral supplements and herbal medicines) within 7 days prior to dosing. 11. Participant has used CYP3A inducers and/or inhibitors (including St. John's Wort) within 30 days prior to dosing. The Indiana University "Cytochrome P450 Drug Interaction Table" should be utilized to determine inducers and/or inhibitors of CYP3A (http://medicine.iupui.edu/clinpharm/ddis/table.aspx). 12. Participant has any surgical or medical conditions possibly affecting drug absorption, distribution, metabolism, and excretion, eg, bariatric procedure. Note: prior appendectomy is acceptable, but prior cholecystectomy would result in exclusion from the study. 13. Participant donated blood or plasma within 8 weeks prior to dosing to a blood bank or blood donation center. 14. Participant has a history of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual [DSM]) within 2 years prior to dosing, or positive drug test reflecting consumption of illicit drugs. 15. Participant has a history of alcohol abuse (as defined by the current version of the DSM) within 2 years prior to dosing, or positive alcohol test. 16. Participant is known to have serum hepatitis or known to be a carrier of hepatitis B surface antigen (HBsAg) or hepatitis C antibody (HCV Ab), or have a reactive result to the test for human immunodeficiency virus (HIV) antibodies at screening. 17. Participant has a history of smoking/use of tobacco or nicotine-containing products within 3 months prior to check-in (Day -1). 18. Participant has received immunization with a live or live-attenuated vaccine within 2 months prior to dosing or is planning to receive immunization with a live or live-attenuated vaccine for 2 months following dosing. 19. Participant participated in a radiolabeled drug study, where exposures are known to the Investigator, within the previous 4 months prior to check-in (Day -1); or participated in a radiolabeled drug study, where exposures are not known to the Investigator, within the previous 6 months prior to check-in (Day -1). The total 12-month exposure from this study and a maximum of 2 other previous studies within 4 to 12 months of this study will be within the CFR-recommended levels considered safe: less than 5000 mrem whole body annual exposure, with consideration given to the half-lives of the previous radiolabeled study drugs received. 20. Participant was exposed to significant radiation (eg, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring) within 12 months prior to check-in (Day -1). 21. History of less than 1 to 2 bowel movements per day. 22. Participant is part of the study site personnel or a family member of the study site staff.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
[14C]-CC-92480
Oral

Locations

Country Name City State
United States Covance Clinical Research Unit Inc Madison Wisconsin

Sponsors (1)

Lead Sponsor Collaborator
Celgene

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cumulative excretion of [14C]-RA The total recovery of radioactivity (RA) will be computed as the sum of the cumulative excretion (as % dose) in urine and feces (and vomit, if applicable). Up to approximately 15 days
Primary Pharmacokinetics -Tmax of total radioactivity, CC-92480 and its metabolites Time to reach maximum total radioactivity or concentration of CC-92480 and its metabolites Up to approximately 15 days
Primary Pharmacokinetics - Cmax of total radioactivity, CC-92480 and its metabolites Maximum total radioactivity or concentration of CC-92480 and its metabolites Up to approximately 15 days
Primary Pharmacokinetics - AUC0-t of total radioactivity, CC-92480 and its metabolites Area under the concentration-time curve from time zero to the last measured time point Up to approximately 15 days
Primary AUC0-inf of total radioactivity, CC-92480 and its metabolites Area under the concentration-time curve from time zero extrapolated to infinite time Up to approximately 15 days
Primary Pharmacokinetics - CL/F of total radioactivity, CC-92480 and its metabolites Apparent oral clearance Up to approximately 15 days
Primary Pharmacokinetics - Vz/F of total radioactivity, CC-92480 and its metabolites Apparent volume of distribution Up to approximately 15 days
Primary Pharmacokinetics - t1/2 of total radioactivity, CC-92480 and its metabolites Terminal elimination half-life Up to approximately 15 days
Primary Metabolic profiling in urines and feces The percentage of the administered dose attributed to CC-92480 and its metabolites in urine and feces Up to approximately 15 days
Secondary Adverse Events (AEs) An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE. From enrollment until at least 28 days after completion of study treatment
See also
  Status Clinical Trial Phase
Completed NCT05029518 - 3-Way Crossover Study to Compare the PK (Pharmokinetics) and to Evaluate the Effect of Food on the Bioavailability Phase 1
Completed NCT05001152 - Taste Assessment of Ozanimod Phase 1
Completed NCT04493255 - A Study to Determine the Metabolism and Elimination of [14C]E7090 in Healthy Male Participants Phase 1
Completed NCT03457649 - IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers Phase 1
Completed NCT00995891 - Collection of Blood, Bone Marrow, and Buccal Mucosa Samples From Healthy Volunteers for Center for Human Immunology, Autoimmunity, and Inflammatory Diseases (CHI) Laboratory Research Studies
Completed NCT05043766 - Evaluation of Oral PF614 Relative to OxyContin Phase 1
Completed NCT05050318 - Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively Phase 4
Completed NCT04466748 - A Multiple Ascending Dose Pharmacology Study of Anaprazole in Healthy Chinese Subjects Phase 1
Completed NCT00746733 - Vyvanse and Adderall XR Given Alone and in Combination With Prilosec OTC Phase 1
Recruiting NCT05929651 - Study of Immunogenicity and Safety of MenQuadfi® as a Booster Vaccine in Toddlers 12 to 23 Months, Regardless of the Quadrivalent Meningococcal Conjugate Vaccine Used for Priming in Infancy Phase 4
Completed NCT05954039 - Evaluation of the Efficacy of a Dietary Supplement on Hair Loss and Hair Aspect N/A
Completed NCT05045716 - A Study of Subcutaneous Lecanemab in Healthy Participants Phase 1
Active, not recruiting NCT02747927 - Efficacy, Safety and Immunogenicity of Takeda's Tetravalent Dengue Vaccine (TDV) in Healthy Children Phase 3
Completed NCT05533801 - A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants Phase 1
Not yet recruiting NCT03931369 - Adaptation of Thirst to a Single Administration of Tolvaptan (TOLVATHIRST) Phase 2
Completed NCT03279146 - A Single Dose Study Evaluating PK of TXL Oral Formulations in Healthy Subjects Phase 1
Completed NCT06027437 - A Study to Assess the Relative Biological Availability and the Effect of Food on the Drug Levels of Danicamtiv in Healthy Adult Participants Phase 1
Recruiting NCT05619874 - Effects of Two Virtual HIFCT Programs in Adults With Abdominal Obesity N/A
Completed NCT05553418 - Investigational On-body Injector Clinical Study N/A
Completed NCT04092712 - Study Evaluating Pharmacokinetics and Mass Balance of [14C]-CTP-543 in Healthy Adult Male Volunteers Phase 1